Dirk Haussecker

@jfais20 Let me know when you come over to practice your German on me.

@RNAiAnalyst Danke mein Lehrer😂😂😂

Fun little hack = interspacing language lessons during DD hours (keeps me on my toes @RNAiAnalyst)

@yaireinhorn @eyeMacLaren @davidrliu @john_evans3 @BeamTx @PrimeMedicine @broadinstitute @zhaoweiasu A simple question: why cant a G to A mutation be addressed by prime editing? I mean isnt $prme making this exact point for AATD? $BEAM

This chart is extracted from an article that was published by Professor Robert McLaren from Oxford in which he divided the different mutations into these different segments. If I would have to choose a rational I would argue that he divided them into frameshifts, dilutions and other more complicated CHM mutations which require a more complicated editing compared to nonsense mutations that are caused by a single letter error. But this is my own interpretation.

The common theme that “Prime Editing $PRME will eventually replace Base Editing $BEAM and make it obsolete” is completely wrong. An example for their irreplaceable and even complementary rule can be seen in an excellent research published by @eyeMacLaren which examined the different prevalent mutations in Choroideremia - a rare, X-linked genetic eye disease that is characterized by the progressive degeneration of the retina, causing childhood night blindness, tunnel vision, and eventual blindness. As this excellent chart shows each CHM mutation would require a different Gene Editing treatment to correct it - whether via a Prime Editing-based treatment or via a Base Editing one. It’s crucial to understand that there will be a need to use a vast range of different genetic medical platforms - CRISPR & Gene Editing, Gene Therapy, RNA Therapy, EpiGenetic Editing and others, in order to provide a treatment for 400 million patients worldwide who are currently suffering from one of the 8,000-10,000 rare genetic diseases known today.

$AMGN execs must believe they will never be held personally accountable and that the out-of-court settlements with the bereaved families are nothing more than a parking ticket instead of admitting guilt.

@canoebrookbl Thank you for your great coverage of this scandal. It critically helped topple the racket. But instead of just 'correcting' mistakes, it is an opportunity to create a much better FDA of the future. Seize the moment.

AV got cleaned house with Marty Makary, Vinay Prasad, Tracy Beth Høeg and Katherine Szarama all out from the FDA. Like I said, FDA needs over correction from the AV/MM/VP fiasco, otherwise more capital will flow to China.

As somebody who lives in a 'third world' country when it comes to access to top medical innovation, Germany, I envision a GLOBALIZED health #insurance future: National systems provide very basic insurance. Individuals can then opt to take out global health insurance that gives them more. The most expensive will cover the latest and greatest medical care. This will also help the pharmaceutical industry, because of instead of relying just on the US market, a global scheme would be even larger. In return, the US would not have to shoulder the financial drug development burden.

#FDA A clean slate is a huge opportunity in enabling the future of healthcare. Body autonomy and maximum flexibility in what is allowed on the market should be the guiding principles. Let the main stakeholder, YOU, decide what's best for you...but you should also have financial skin in the game. The $srpt vs $rgnx debate is instructive: $srpt was first on the market with a gene therapy for DMD, now $rgnx has to deliver the evidence that they are better. Correlating gene expression with performance is one important step in that direction. The more competition, also in the post-market period, the better for the patient. The patient is not dumb. We live in the AI age. The physician is there to be his coach and perform procedures. Remove the gatekeepers.

$repl $qure Arnold hack Szarama OUT as CBER acting director, ex- $amrn CEO Mikhail IN!

Latest on the post-Makary turmoil across the Food and Drug Administration: cnn.com/2026/05/15/pol…

@JasonGreenwal12 Is this the reason why the $xbi was down 3% today?

Makary forget he resigned and forgot to turn off auto tweeting, fucking moron

Wow, $AMGN is in deep trouble. Why risk it? The FDA actually gave them an out and they refused it.

$BEAM in a normal market would have taken advantage of recent weakness ahead of additional AATD data. Response over time of interest. But with widespread kinetic action in Iran likely after market close and the bond market showing signs of increased inflation worries, I will pass on added exposure.

@mike98572986 @biggercapital @peter_mantas The ASCGT must be following the principle of keeping your friends close, your enemies closer.

$qure $clpt This had to be hilarious, a conversation with KATHERINE SZARAMA Wish we could be a fly on the wall on that one. @biggercapital @peter_mantas

WIFI next after HOEG? reuters.com/world/fda-drug…

@bundeskanzler @POTUS Heisst das, dass Deutschland Trump bei Wiederaufnahme von Kriegshandlungen nun unterstuetzen wird und vorige Aeusserungen der Bundesregierung, dass der Krieg nicht zwingend war, nun einfach vergessen werden? What's in it for us?

I had a good phone call with @POTUS Donald Trump on his way back from China. We agree: Iran must come to the negotiating table now. It must open the Strait of Hormuz. Tehran must not be allowed to have nuclear weapons. (1/2)

@GeneInvesting @houmanhemmati @tracegallagher @foxnewsnight The inability to patent targets('genes') per se and then have competitors immediately crowd around them after you have done the hard/risky work is a key problem.

@houmanhemmati @tracegallagher @foxnewsnight Yes! I’m not sure why our government is allowing Big Pharma to buy all of these Chinese biotechs… considering many are copycat companies and steal IP.

🇺🇸 🇨🇳 TONIGHT: I’m honored to join @tracegallagher & an amazing group of guests & journalists on a special 2 hour edition of @foxnewsnight starting an hour EARLY (7p PT / 10p ET) to discuss the historic US/China summit. I’ll be discussing how China is threatening to overtake the U.S. on life science innovation & manufacturing, and how the US administration can address that through investment & regulatory changes.

@LauraPowellEsq They are now in the gym doing peptides.

The decrease in alcohol use among teens correlates with a decrease in socializing, an increase in time spent alone, and worsening mental health.

Everyone recognizes this as a symptom of something bad, right?

@Steve72354669 Why would anybody buy a dying biotech company...they rather deal with a fresh, aspiring AI-native start-up developing the next-generation Fabry therapy etc. $sgmo

@RNAiAnalyst Really sad state of affairs why the company is not fully for sale is beyond me.

$sgmo how do they even keep the lights on at this point?

This is true. In Europe, many would literally still be alive, and even more not suffer from the side effects of outdated drugs... ...if they had access to all the biotech innovations (most) US residents have. Only with private health insurance and a lot of pushing do I, as a German, even stand a chance to access them (big) IF they are even marketed here. Something's got to give.